Hemogenyx Pharmaceuticals Share Discussion Threads

[orchestralis] 21/4/2020 08:47

Are you talking to yourself?

[purple11] 21/4/2020 08:25

once again true to form

ffs
zzzzzzzzzzzzzzzzzzzzzzzzz……...…...…...…...

[purple11] 20/4/2020 20:10

don't be so rude!

[johntopdog] 20/4/2020 15:56

So how many shares do you actually own purple...and what is your average ?

[purple11] 20/4/2020 15:38

I notice you just topped up:)gl hang onto those 20 shares and they could be worth a pound soon.

#player

[purple11] 20/4/2020 13:05

1.65 -1.85

a ridiculous spread.
don't they just love to drop the bid......

[purple11] 20/4/2020 13:03

youre talking about marie.

and clearly shes unstable.

[purple11] 20/4/2020 12:44

I never said it was a scam.

Sir Mark Fieldmann wouldn't head a scam.

[johntopdog] 20/4/2020 12:40

The other week purple you said..

I wish I had never heard of this share !

You also said it was a scam ..

Yes you are very informative! all you can do is moan or cut and paste .

[purple11] 20/4/2020 12:16

do one.
my posts are informative unlike yours.
stay on the numpty thread .

the thread for yobs.

[johntopdog] 20/4/2020 11:29

Give it a rest purple....7 posts before 11am...

Time you took a break from posting

[purple11] 20/4/2020 10:06

CLINICAL READINESS

so come on get the deal!

[purple11] 20/4/2020 10:06

then in November 2019

CDX Antibodies

GlobalCo development agreement

Work with a global international pharmaceutical company ("GlobalCo") on the Company's CDX antibody ("CDX") as a clinical candidate, first announced on 14 May 2018, has entered its second phase. The Company and GlobalCo continue to develop CDX towards clinical readiness and have initiated manufacturability assessment and follow-up tests of the antibody.

Hemogenyx and GlobalCo remain optimistic as to the outcome of these tests based on results to date and look forward to providing further updates as the development work progresses.

[purple11] 20/4/2020 10:04

this was later I September 2019

Continued progress towards the goal of submitting an Investigational New Drug ("IND") application to the US Food and Drug Administration ("FDA") for CDX antibodies
· Preliminary discussions regarding a potential licensing deal are continuing with the global biopharmaceutical company following a Development Agreement announced in May 2018

[purple11] 20/4/2020 09:59

anyway we are now in the "second phase" of talks with the global co.

lets see what they've got.

[purple11] 20/4/2020 09:55

from april 2019
Agreement with global bio-pharmaceutical company to develop the Company's CDX antibodies - potential for licensing deal

Work on CDX antibodies is progressing well and we have initiated discussions with a global pharmaceutical company on a potential licensing deal.


so whats happening?

time to put up or shut up.you cant just put out this type of information to the market if its not going to happen.

[purple11] 20/4/2020 09:51

from april 2019
Progress continues towards the submission of an Investigational New Drug ("IND") application for a CDX antibody, the Company's lead product candidate

so when is this getting done?

[purple11] 20/4/2020 09:39

the final results were on 29 april last year so should be coming up shortly.
hopefully hear more about the second phase of negotiations with global co agreement.

[purple11] 20/4/2020 08:14

hemo is trading roughly at the last placing price.its cheap imo
the crazy stockmarket crash prices we wont see again.

bring on some newsflow.

[tullynessle] 20/4/2020 07:17

It would be interesting to identify if Hemogenyx / Immugenyx have applied for funding in respect of their USA operations similar to the loans, (or conditional grants), achieved by TRX, as reported in the RNS this morning.

[Aside: Tissue Regenix is a leading medical devices company in their field of regenerative medicine.]




Tissue Regenix Group PLC Additional US government-backed loan secured
20 April 2020

Additional US government-backed loan secured

Leeds, 20 April 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix", the "Group" or the "Company"), the regenerative medical devices Company, announces that the Group has received a further $417,000 loan (the "Loan") under the US government backed COVID-19 business support scheme. The funds in respect of the Loan have already been received by the Company.

This funding is in addition to the receipt of a US government-backed loan of $629,000, announced on the 15 April 2020, and combined, offer over $1m of US government support during the COVID-19 pandemic.

Both Loans are subject to the same conditions, which include a two-year term and carry a 1% annual interest rate deferred for six months. However, under the Loan agreements, the principal will not require repayment if the funds are used to support employee payroll, healthcare, utilities and rent payments within the US during the next two months. The Company intends to use the funds to support these activities and therefore expects the Loan not to require repayment.

[johntopdog] 19/4/2020 20:37

I see Hemogenyx have retweeted on a tweet about COVID 19 testing .....I presume there is something behind this given recent news....exciting week ahead

[idontflykathyy] 18/4/2020 11:47

Purple,

Seems like there is still life here ;-)

Attach word Covid and anything just shoot Up.

Around 3p, perfect opportunity for LTH to quit yeah..

[knowing] 17/4/2020 15:32

Need both to make a market

[jibba jabber] 17/4/2020 14:50

There's a 1mln worked sell and explains the price action.